Maternal supraphysiological hypercholesterolemia associates with endothelial dysfunction of the placental microvasculature by Fuenzalida, Bárbara et al.
1SCientifiC REPORtS |  (2018) 8:7690  | DOI:10.1038/s41598-018-25985-6
www.nature.com/scientificreports
Maternal supraphysiological 
hypercholesterolemia associates 
with endothelial dysfunction of the 
placental microvasculature
Bárbara Fuenzalida1, Bastián Sobrevia1, Claudette Cantin1, Lorena Carvajal1, Rocío Salsoso1, 
Jaime Gutiérrez1,2, Susana Contreras-Duarte1, Luis Sobrevia1,3,4 & Andrea Leiva1
Maternal physiological or supraphysiological hypercholesterolemia (MPH, MSPH) occurs during 
pregnancy. MSPH is associated with foetal endothelial dysfunction and atherosclerosis. However, the 
potential effects of MSPH on placental microvasculature are unknown. The aim of this study was to 
determine whether MSPH alters endothelial function in the placental microvasculature both ex vivo in 
venules and arterioles from the placental villi and in vitro in primary cultures of placental microvascular 
endothelial cells (hPMEC). Total cholesterol < 280 mg/dL indicated MPH, and total cholesterol 
≥280 mg/dL indicated MSPH. The maximal relaxation to histamine, calcitonin gene-related peptide and 
adenosine was reduced in MSPH venule and arteriole rings. In hPMEC from MSPH placentas, nitric oxide 
synthase (NOS) activity and L-arginine transport were reduced without changes in arginase activity 
or the protein levels of endothelial NOS (eNOS), human cationic amino acid 1 (hCAT-1), hCAT-2A/B 
or arginase II compared with hPMEC from MPH placentas. In addition, it was shown that adenosine 
acts as a vasodilator of the placental microvasculature and that NOS is active in hPMEC. We conclude 
that MSPH alters placental microvascular endothelial function via a NOS/L-arginine imbalance. This 
work also reinforces the concept that placental endothelial cells from the macro- and microvasculature 
respond differentially to the same pathological condition.
Maternal levels of total cholesterol (TC) increase as human pregnancy progresses, i.e., maternal physiological 
hypercholesterolemia in pregnancy (MPH), to satisfy the demand of this lipid by the growing foetus1. However, 
some pregnant women show an excessive increase in TC, mainly due to an increase in the low-density lipoprotein 
cholesterol (LDL) level, a condition regarded as maternal supraphysiological hypercholesterolemia in pregnancy 
(MSPH)2,3. MSPH and increased maternal LDL levels are associated with endothelial dysfunction of the umbil-
ical vein1,3–5 and early development of atherosclerosis in the foetal aorta6,7. MSPH is diagnosed in women with 
TC levels over a cut-off value of 280–290 mg/dL at term or over the 75th percentile for the different trimesters 
of pregnancy4,6–10. MSPH is associated with impaired nitric oxide (NO)-dependent dilation of human umbilical 
vein rings3,4. NO is synthesized by nitric oxide synthases (NOS). Particularly, endothelial NOS (eNOS) metab-
olize the amino acid L-arginine to nitric oxide and citrulline1. In placental endothelial cells, L-arginine is trans-
ported to the intracellular space by the human cationic amino acid transporter 1 (hCAT1), 2A and 2B (hCAT 
2 A/B)11,12. In addition, L-arginine can be metabolized by other enzymes as arginases that compete with eNOS 
for substrate13,14. In human umbilical vein endothelial cells (HUVEC) isolated from MSPH pregnancies, reduced 
NOS activity, increased endothelial L-arginine uptake, and increased expression and activity of arginase II have 
been reported3,5. In addition, foetuses developed under MSPH conditions have increased atherosclerotic lesions 
in the aorta at birth6 and in childhood7. This phenomenon is also associated with increased markers of oxidative 
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stress both in HUVEC from MSPH pregnancies5 and in maternal and neonatal circulation8. Therefore, it has been 
proposed that MSPH could be a crucial condition that increases the risk of an adverse foetal outcome and risk of 
developing cardiovascular diseases later in life1,15,16. In this scenario, the role of the placenta and the consequences 
of MSPH on the endothelial function of the placental microvasculature are still unknown.
Endothelial cells from different organs as well as from large and small vessels (i.e., macro- and microvascu-
lature) of the same organ have specialized properties. In the human placenta, microvascular endothelial cells 
(hPMEC) function as a metabolic barrier, maintaining proper nutrient exchange between maternal and foetal 
circulation11,17,18. The expression of eNOS has been described in endothelial cells from the microvasculature; how-
ever, the activity or modulation of this enzyme by maternal pathological conditions such as MSPH is unknown11,19.
Therefore, the aim of this work was to determine the effects of MSPH on endothelial function in small vessels 
of the placenta ex vivo in microvenules and arterioles from the placental villi as well as in vitro in primary cultures 
of placental microvascular endothelial cells.
Methods
Study groups. Human placentas were collected from 20 normal full-term pregnancies (Table 1) from 
the Hospital Clínico UC-CHRISTUS (HCUC). The investigation conformed to the principles outlined in the 
Declaration of Helsinki. Ethics committee approval from the Faculty of Medicine of the Pontificia Universidad 
Católica de Chile (authorization number 11-066) and informed consent from patients were obtained. General 
maternal (i.e., age, height, weight, blood pressure and glucose levels) and neonatal (i.e., sex, gestational age, 
weight and height) variables were obtained from the clinical records. All pregnant women were screened for 
plasma levels of TC, high-density lipoprotein (HDL), LDL or very-low-density lipoprotein (VLDL) cholesterol 
and triglycerides (TG) at term of pregnancy (third trimester)3,4. Women with TC < 280 mg/dL were considered to 
have MPH, and those with TC ≥ 280 mg/dL were considered to have MSPH; these cut-off values for MSPH reflect 
values at which human fetoplacental endothelial and vascular dysfunction have been observed, as previously 
reported3–8. The exclusion criteria were maternal obesity at term of pregnancy, pre-gestational and gestational 
diabetes, preeclampsia, intrauterine growth restriction, foetal malformations or other maternal pathologies. Thus, 
among the 116 women who participated in this study, only 20 were included. The remaining 96 women were 
excluded based on the exclusion criteria.
Plasma cholesterol and triglyceride measurement. TC, HDL, LDL, VLDL and TG levels were deter-
mined in maternal plasma obtained from brachial venous blood at the time of delivery. Lipid determination was per-
formed in the Clinical Laboratory of the HCUC via standard enzymatic-colorimetric assays as previously described3.
Variables MPH (n = 12) MSPH (n = 8)
Maternal variables
Age (years) 30.6 ± 1.4 (19–36) 30 ± 1.9 (25–39)
Height (cm) 161 ± 1.6 (152–168) 161 ± 1.9 (156–167)
Weight at delivery (kg) 74.4 ± 2.1 (61–85) 72 ± 3.8 (64–89)
BMI at delivery (kg/m2) 29.4 ± 1 (27–30) 28.5 ± 1.9 (23–30)
Mean arterial pressure at delivery 
(mmHg) 83.7 ± 1.8 (77–97) 82.8 ± 2.7 (70–91)
Basal glycemia (mg/dL) 76.7 ± 2 (68–84) 76.5 ± 3.5 (73–80)
OGTT (mg/dL)
  Basal glycemia 77.4 ± 1.6 (73–82) 76.5 ± 3.5 (73–80)
  Glycemia 2 h after glucose 97.0 ± 4.4 (87–112) 99.5 ± 14.5 (85–114)
Lipid levels at delivery (mg/dL)
  Total cholesterol 234.6 ± 33 (183–275) 331 ± 16* (295–356)
  HDL 64.4 ± 16 (48–100) 61 ± 12 (49–80)
  LDL 117 ± 26 (80–150) 190.1 ± 39* (129–227)
  VLDL 62.6 ± 28 (36–132) 58.4 ± 25 (49–68)
Triglycerides 246.9 ± 93 (80–426) 292 ± 50 (244–342)
New-born variables
Sex (female/male) 7/5 4/4
Gestational age (weeks) 39.3 ± 0.4 (37–41) 39.1 ± 0.7 (37–41)
Birth weight (grams) 3536 ± 140 (2580–4170) 3490 ± 144 (2900–4000)
Height (cm) 51.2 ± 0.8 (45–54) 52.2 ± 0.8 (50–56)
Ponderal index (grams/cm3 × 100) 2.63 ± 0.08 (2.22–3.11) 2.45 ± 0.08 (2.07–2.76)
Table 1. Clinical characteristics of pregnant women and new-borns. Women with maternal physiological 
(MPH, TC < 280 mg/dL) or supraphysiological hypercholesterolemia (MSPH, TC ≥ 280 mg/dL) at delivery were 
included (see Methods). Weight, body mass index (BMI), blood pressure and lipid profiles were determined 
at delivery. OGTT, oral glucose tolerance test. HDL, high-density lipoproteins; LDL, low-density lipoproteins; 
and VLDL, very-low-density lipoproteins. *P < 0.05 versus corresponding values in the MPH group. Data are 
presented as the mean ± S.D. (range).
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Human placental microvascular reactivity. Isometric force was measured in a myograph using 
microvessels isolated from placental type I stem villous20–24. In brief, isolated cotyledons were obtained from the 
placenta, and the chorionic plate and decidua were removed. Small vessels were identified under a stereomicro-
scope and dissected from the surrounding trophoblastic and connective tissue. Arterioles and venules (arterioles: 
200–300 μm; venules: 200–500 μm) were identified by size and morphology and were carefully cut into rings of 
approximately 2 mm in length. The vessels were mounted onto a DMT 620 M wire myograph.
The internal diameter of the vessels as well as the optimal diameter for all the experiments was determined 
by the normalization module of the myograph (DMT normalization module in AD Instruments LabChart 7 
software). All the rings were normalized to a luminal pressure of 50 mmHg21. The vessels were pre-constricted 
with 32.5 mmol/L KCl or 1 μmol/L serotonin, and then, the dilation in response to histamine (0.01–1000 μmol/L, 
5 min)21,25, calcitonin gene-related peptide23 (CGRP, 0.01–1000 nmol/L, 5 min) or adenosine (0.01–1000 μmol/L, 
5 min) was recorded in the absence or presence of 100 μmol/L NG-nitro-L-arginine methyl ester (L-NAME, 
NOS inhibitor, 30 min) or 10 μmol/L sodium nitroprusside (SNP, NO donor, 5 min), as previously reported24,25. 
Relaxation of the vessels was expressed as the percentage of relaxation caused by the different molecules com-
pared to maximal contraction. The concentration of the drug required to produce 50 percent of the maximum 
relaxation (EC50) was calculated using the program GraphPad Prism.
Cell culture. Human placental endothelial microvascular cells (hPMEC) were isolated by trypsin/collagenase 
digestion from placental villous tissue from MPH or MSPH pregnancies and cultured as described elsewhere26–28. 
In brief, placental sections were obtained after delivery, and the decidua and chorionic plate were removed. After 
that, larger vessels and calcifications were removed, and the tissue was carefully minced. The tissue was later 
digested with trypsin/EDTA (final concentration: 0.05%, 20 min, 37 °C). The digestion was stopped with foetal 
bovine serum (FBS, final concentration: 1%), and the tissue was centrifuged (1000 RCF, 5 min, 4 °C). The tissue 
was later digested with type II collagenase (0.1 mg/mL, 2 h, 37 °C) (Worthington, USA) in culture medium 199 
(M199). After that, the digestion was stopped with M199 supplemented with FBS (final concentration : 1%) and 
centrifuged (300 RCF, 5 min, 4 °C). The supernatant, which contained the cells, was obtained and centrifuged 
(1500 RCF, 10 min, 4 °C). The cellular pellet was cultured in M199 supplemented with FBS (20%) and new-born 
calf serum (NBCS, 20%). After confluence, the cells were trypsinized and subjected to positive immunoselection 
using CD31 Dynabeads (Thermo Fisher scientific, USA). Cells were cultured in M199 medium containing FBS 
(10%), NBCS (10%), 3.2 mmol/L L-glutamine and 100 u/mL penicillin-streptomycin under standard conditions 
(37 °C, 5% CO2). Cells were positive for CD31 and von Willebrand factor (endothelial markers) and negative for 
alpha smooth muscle (muscle marker) expression11.
Western blotting. Total proteins were separated by polyacrylamide gel electrophoresis, transferred to pol-
yvinylidene difluoride membranes and later probed with primary polyclonal rabbit anti-total eNOS (1:200, 2 h, 
room temperature), polyclonal goat anti-hCAT-1 (1:200, 18 h, 4 °C), polyclonal goat anti-hCAT-2A/B (1:200, 
2 h, room temperature), or polyclonal rabbit anti-ARGII (1:200, 18 h, 4 °C) (Santa Cruz Biotechnology, Santa 
Cruz, CA, USA) and monoclonal mouse anti-ß-actin (1:5000, 1 h, room temperature) (Sigma Aldrich, Germany) 
antibodies as previously described3. Membranes were rinsed and incubated (1 h, room temperature) with sec-
ondary horseradish peroxidase-conjugated rabbit anti-goat, goat anti-rabbit or anti-mouse antibodies (Santa 
Cruz Biotechnology). Proteins were detected by enhanced chemiluminescence and quantified by densitometry  
(Supplementary information).
NOS activity. NOS activity was assayed by determining the intracellular content of L-citrulline by 
high-performance liquid chromatography (HPLC) as previously reported5,29. Briefly, confluent hPMEC were incu-
bated (30 min, 37 °C) with HEPES buffer solution ((mmol/L) 50 HEPES pH 7.4, 100 NaCl, 5 KCl, 2.5 CaCl2, 1 
MgCl2) supplemented with 100 μmol/L L-arginine in the absence or presence of 100 μmol/L L-NAME. After that, 
the cells were homogenized by sonication, and the proteins were quantified (BCA Protein Assay Kit, Thermo Fisher 
Scientific). Proteins were precipitated by the addition of HClO4 (1.5 mol/L) and K2CO3 (2 mol/L). After centrif-
ugation (10000 RCF, 2 min, 4 °C), the amino acids in the supernatant were determined. L-citrulline content was 
estimated in samples derivatized with 14 mmol/L sodium borate and 4 mmol/L o-phtalaldehyde and injected in a 
C18 column (HiQsil, KYA Tech, Japan) coupled to an HPLC system (PU2089s, Jasco, Japan). The mobile phase was 
0.1 mol/L NaH2PO4, pH 5.0 and 17% acetonitrile (0.7 mL/min flux rate). Fluorescence was monitored at excitation 
and emission wavelengths of 340 and 450 nm, respectively. The L-citrulline concentration was determined against 
a standard curve with the software ChromPass 1.7 (ChromPass Chromatography Data System, Jasco, Japan). All 
the values were corrected by the protein content in each sample. L-NAME-inhibited L-citrulline formation was 
estimated by the difference between values obtained in cells in the absence and in the presence of L-NAME.
L-arginine uptake and transport. L-Arginine uptake (125 μmol/L L-arginine) and L-arginine transport 
(0–1000 μmol/L L-arginine) (3 μCi/mL L-[3H]arginine (Perkin-Elmer, USA), 1 min, 37 °C) were measured in 
hPMEC pre-incubated (overnight) in M199 containing NBCS (1%) and FBS (1%), as previously described30. The 
overall initial transport rates (i.e., the linear uptake for 1 min) were adjusted to the Michaelis-Menten hyperbola, 
and the maximal velocity (Vmax) and apparent Michaelis-Menten constant (Km) were calculated as previously 
described3,30. Maximal L-arginine transport capacity was estimated as Vmax/Km. The relative effect of MSPH versus 
MPH on the maximal L-arginine transport capacity (MSPH/MPHF) was estimated as [(Vmax/Km)MSPH/(Vmax/Km)MPH]3.
Arginase activity. Arginase activity was estimated as total urea production from L-arginine. Enzymatic 
activity was measured in 70 μg of protein obtained after the lysis of hPMEC, as previously described3,31. In brief, 
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70 μg of protein was pre-incubated (10 min, 55 °C) with 100 mmol/L MnCl2 in 50 mmol/L Tris-HCl (pH 7.5) 
and then mixed with L-arginine (50 mmol/L, 60 min, 37 °C, pH 7.4). The reaction was stopped by the addition 
(400 μL) of an acid mixture (H2SO4:H3PO4:H2O = 1:3:7 v/v). Finally, the reactions were incubated (45 min, 100 °C) 
in 9% a-isonitrosopropiophenone solution for colorimetric determination of urea by absorbance at 540 nm. Each 
assay was performed in duplicate, and enzymatic activity was expressed as pmol urea/μg protein/min.
Statistical analysis. Values for maternal and neonatal characteristics are presented as the mean ± S.D. For 
ex vivo and in vitro assays, the values are presented as the mean ± S.E.M., where n indicates the number of placen-
tas (MPH = 5 and MSPH = 7) or cell cultures (MPH = 6 and MSPH = 6) used for the ex vivo and in vitro assays, 
respectively. Comparisons between two or more groups were performed by non-parametric (Mann-Whitney or 
Friedman test, respectively) tests. P < 0.05 was considered statistically significant.
Data availability. The datasets generated during and/or analysed during the current study are available from 
the corresponding author on reasonable request.
Results
Study groups. All the evaluated maternal and neonatal general variables were similar between MSPH and 
MPH pregnancies (Table 1).
Maternal lipid levels. The maternal plasma TC and LDL levels at term of pregnancy were higher in MSPH 
pregnancies than in MPH pregnancies. HDL, VLDL and TG levels were not altered by MSPH (Table 1).
Human placental microvascular reactivity. Endothelium-dependent vascular dilation was evaluated 
in venules and arterioles isolated from MPH and MSPH placentas. Histamine (Fig. 1a), CGRP (Fig. 1b) and 
adenosine (Fig. 1c) induced vascular dilation in venule and arteriole rings from the placental microvasculature 
(Table 2). Histamine, CGRP and adenosine caused lower maximal dilation (Dmax) in venule and arteriole rings 
from MSPH placentas than in those from MPH placentas (Fig. 1a–c, Table 2). In MPH vessels, inhibition of NOS 
activity with L-NAME caused a partial reduction in histamine-mediated dilation in venule (11.8 ± 3%) and arte-
riole (42.9 ± 6%) rings (Fig. 1d). However, CGRP- and adenosine-induced dilation was almost abolished in the 
presence of L-NAME both in venules and arterioles from MPH placentas (Fig. 1d). The effects of the inhibition of 
NOS activity on dilation (in the presence of L-NAME) were lower in MSPH venules and arterioles than in MPH 
vessels (Fig. 1e). To determine the effects of NO, the vessels were exposed to the NO donor SNP, which caused 
comparable dilation in rings from MPH and MSPH placentas (Fig. 1f). MSPH was not associated with changes in 
the EC50 for histamine in venule or arteriole rings or the EC50 for CGRP in venules (Table 2). The EC50 for CGRP 
in arterioles and the EC50 for adenosine in arterioles and venules from MSPH placentas were not measurable due 
to the reduced dilation of these vessels (Table 2).
NOS activity and eNOS expression. To determine NOS activity in endothelial cells from the microvas-
culature, L-citrulline formation was evaluated in hPMEC isolated from MPH and MSPH placentas. L-citrulline 
formation under basal conditions in hPMEC from MSPH placentas was lower than that in MPH cells, and 
incubation with L-NAME reduced L-citrulline formation in MPH cells but not in MSPH cells (Fig. 2a). Thus, 
L-NAME-inhibited L-citrulline formation was higher (5.87-fold) in MPH cells (0.00793 pmol/µg protein) than in 
MSPH cells (0.00135 pmol/µg protein) (Fig. 2b). Total eNOS protein abundance was not different between MSPH 
and MPH hPMEC (Fig. 2c).
L-arginine transport. To determine the availability of the substrate of NOS for NO synthesis, the uptake of 
L-arginine was evaluated in hPMEC isolated from MPH and MSPH placentas. L-Arginine uptake at 125 μmol/L 
L-arginine was lower in hPMEC from MSPH placentas than in those from MPH placentas (Fig. 3a). To determine 
whether this change was also associated with changes in the kinetic parameters for the transport of the amino 
acid, the transport of L-arginine was evaluated. Overall L-arginine transport was saturable in MPH and MSPH 
cells (Fig. 3b). In hPMEC from MSPH placentas, L-arginine transport exhibited lower Vmax and Vmax/Km but 
higher Km than that in cells from MPH placentas (Fig. 3b, Table 3). Thus, it was estimated that L-arginine trans-
port, evaluated as the relative effect of MSPH versus MPH on the maximal L-arginine transport capacity (MSPH/
MPHF), was reduced in cells from MSPH pregnancies (Table 3). Parallel assays showed that neither the protein 
abundance of hCAT-1 nor that of hCAT-2A/B was altered in cells from MSPH pregnancies compared with those 
from MPH pregnancies (Fig. 3c).
Arginase activity. To determine a possible role for arginases in the reduced formation of L-citrulline in 
hPMEC from MSPH placentas, arginase activity was assayed in hPMEC isolated from MPH and MSPH placentas. 
Cells from MSPH placentas exhibited lower arginase activity than those from MPH placentas (Fig. 4a). Arginase 
I protein was not detectable (data not shown) in hPMEC, and arginase II protein abundance was not different 
between MSPH and MPH hPMEC (Fig. 4b).
Discussion
This study shows for first time that increased levels of maternal TC and LDL in MSPH are associated with 
endothelial dysfunction of the human placental microvasculature, likely due to an imbalance between NOS activ-
ity and L-arginine transport.
We showed vascular alterations in the microvasculature of placentas from women with levels of TC over a 
cut-off value of 280 mg/dL. However, this value is suggested as a surrogate marker for placental dysfunction. At 
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Figure 1. Human placental microvascular reactivity. Vascular dilation was determined in venule (□) and 
arteriole (○) rings obtained from human placental type I stem villous from pregnancies during which the 
mother exhibited MPH (white) or MSPH (black). Response to histamine (0.01–1000 μmol/L, 5 min, a), 
calcitonin gene-related peptide (0.01–1000 nmol/L, CGRP, 5 min, b) or adenosine (0.01–1000 μmol/L, 5 min, c) 
in vessels pre-incubated with KCl (32.5 mmol/L). The percentage of inhibition of maximal dilation in response 
to histamine, CGRP and adenosine was determined in the presence of NG-nitro-L-arginine methyl ester 
(L-NAME, 100 µmol/L, 30 min) in MPH (d) and MSPH (e) venules (white) and arterioles (black). (f) Dilation in 
response to sodium nitroprusside (10 μmol/L, 5 min) in vessels from MPH (white) or MSPH placentas (black). 
In (a–c) and (f), the data are expressed as a percentage of maximal dilation in response to KCl. *P < 0.05 versus 
the MPH values. #P < 0.05 versus the venule values. †P < 0.05 versus the CGRP and adenosine values. Values are 
presented as the mean ± S.E.M. (n = 5–7).
Vasoactive molecule
LogEC50 (mol/L) Dmax (%)
MPH MSPH MPH MSPH
Histamine
Venule −4.8 ± 0.27 −4.46 ± 0.39 38 ± 4.1 14.4 ± 6*
Arteriole −4.91 ± 0.41 −4.45 ± 1.17 35.2 ± 5 6.9 ± 7.1*
CGRP
Venule −7.58 ± 0.44 −7.91 ± 3.24 32.3 ± 8.2 1.5 ± 6.3*
Arteriole −7.48 ± 0.43 n.m 28 ± 7.8 −7 ± 9.7*
Adenosine
Venule −3.93 ± 0.17 n.m 53.2 ± 6.8 7.4 ± 2.7*
Arteriole −4.16 ± 0.26 n.m. 36.3 ± 7.7 6.3 ± 4*
Table 2. Dilation in human microvascular placental vessels. Placentas from women with maternal physiological 
(MPH, TC < 280 mg/dL) or supraphysiological hypercholesterolemia (MSPH, TC ≥ 280 mg/dL) in pregnancy 
were included (see Methods). CGRP, calcitonin gene-related peptide. Log EC50, half maximal effective 
concentration. Dmax, maximal dilation. n.m., not measurable. *P < 0.05 versus the corresponding values in the 
MPH group. Values are presented as the mean ± S.E.M (n = 3–7).
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TC levels over 280 mg/dL, changes in both the foetal vasculature (i.e., increased foetal atherosclerosis6,7, markers 
of oxidative stress8 and differential fatty acid composition8 in the foetal blood) and the placenta (i.e., umbilical 
vein endothelial dysfunction3–5, changes in the placental expression of lipoprotein receptors and cholesterol trans-
porters9,10) without changes in new-born size and weight, or in neonatal levels of TC, LDL, HDL, or TG have been 
described3,4,9. Despite that, determination of early markers of endothelial dysfunction or metabolic changes in 
the neonates from MSPH would be necessary to associate this maternal condition with changes in the neonatal 
outcome. In addition, increased maternal TC has also been associated with higher atherosclerotic lesions in the 
childhood9 and elevated lipid levels in the adulthood32 of the offspring. Thus, it has been proposed that MSPH 
may be a maternal condition required for proper placental function with consequences on foetal vascular health 
during pregnancy and later in life1,16,32,33.
There is cumulative experimental evidence showing that macrovascular and microvascular endothelial cell 
function is different, even within the same vascular bed; this phenomenon is required for proper vascular home-
ostasis18,26,34. Therefore, in addition to describing the detrimental effects of MSPH on endothelial function in the 
placental microvasculature, our study also shows that endothelial cells from the macro- and microvasculature 
respond to the same pathological conditions by reducing NOS activity; however, the mechanism leading to this 
reduction may be different.
Since the human placenta lacks innervation, local synthesis and release of vasoactive molecules lead to acute 
and rapid modulation of the vessel tone in this vascular bed35. In addition, classical endothelium-dependent 
vasodilators, such as acetylcholine or bradykinin, have minimal vasodilator effects on this vascular bed, and mol-
ecules such as histamine and CGRP have been used as vasodilators for fetoplacental vessels21,23,25. In this study, we 
showed for the first time that the nucleoside adenosine has vasodilator effects on the placental microvasculature 
both in venules and arterioles isolated from placental type I stem villous (Fig. 1c). As previously demonstrated in 
umbilical vein rings36, the vasodilator effect of adenosine on the placental microvasculature may depend on NOS 
activity in the endothelium, as was shown by the inhibition of its vasodilator effect in the presence of L-NAME 
(Fig. 2d,e). The effects of adenosine on this vascular bed may be due to and modulated by adenosine recep-
tors (ARs) (i.e., A2AAR and A2BAR) and adenosine transporters (hENT1 and hENT2), which are functionally 
expressed in these microvascular endothelial cells26,37.
Regarding the effects of MSPH on microvascular dilation, we showed that the maximal response (Dmax) to 
histamine, CGRP and adenosine was reduced in venule and arteriole rings from MSPH placentas (Fig. 1a–c, 
Figure 2. NOS activity. (a) L-citrulline content in hPMEC from pregnancies during which the mother 
exhibited MPH or MSPH. Cells were pre-incubated with L-arginine (100 μmol/L, 30 min) in the absence 
(white) or presence (black) of 100 μmol/L NG-nitro-L-arginine methyl ester (L-NAME, 30 min). (b) L-NAME 
inhibited L-citrulline content (from the data in a) in hPMEC from MPH (white) and MSPH (black) placentas. 
(c) Representative western blot for total eNOS expression in MPH or MSPH cells (ß-actin: internal control). 
Lateral panel: eNOS/ß-actin densitometry ratios normalized to 1 in the MPH group. In (a), *P < 0.05 versus 
values in the absence of L-NAME, †P < 0.05 versus MPH values. In (b), *P < 0.05 versus MPH values. Values are 
presented as the mean ± S.E.M. (n = 6).
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Table 2) without changes in their sensitivity (EC50) (Table 2). Since the effects of CGRP and adenosine were 
almost abolished by NOS inhibition with L-NAME (Fig. 1d,e), we suggest that the response to these molecules is 
dependent on NOS activity in the endothelium, a phenomenon that may be impaired in MSPH vessels. In MSPH 
vessels, the inhibitory effect by L-NAME was reduced compared with that in MPH vessels, possibly because vessel 
relaxation was significantly lower in MSPH vessels than in MPH vessels (Fig. 1d,e). In addition, the effect of his-
tamine on MPH vessels was partially inhibited by L-NAME, a result that is consistent with previous data showing 
that the effect of histamine on the placental vasculature depends on the expression of histamine receptors both in 
the endothelium and in the smooth muscle38. Since dilation caused by SNP (NO donor) was unaltered in MSPH 
vessels (Fig. 1f) and the L-NAME-inhibited response to CGRP and adenosine was reduced in MSPH vessels, 
we suggest that the endothelium, rather than the smooth muscle, is likely affected by MSPH. Thus, impaired 
microvascular endothelial function may be present in MSPH. However, these results need to be confirmed using 
endothelium-denuded vessels.
To determine whether placental microvascular endothelial cell function was altered in MSPH, NOS activity 
was evaluated in hPMEC isolated from MSPH placentas. Previous studies have shown that eNOS expression in 
hPMEC is lower than that in HUVEC or placental homogenate11 and that eNOS is expressed in the endothe-
lium from the sub-chorionic plate villi but only slightly expressed in small vessels from the terminal villi19,39,40. 
However, NOS activity, as assayed by nitrite determination, was not detectable in hPMEC11. The placental tissue 
used for the preparation of hPMEC is heterogeneous; thus, isolation of microvascular endothelial cells from 
Figure 3. L-arginine transport. (a) Uptake of L-arginine (125 μmol/L, 1 min) in hPMEC from pregnancies 
during which the mother exhibited MPH (white) or MSPH (black). (b) Saturable L-arginine transport (0–
1000 μmol/L, 1 min) in hPMEC from MPH or MSPH placentas. (c) Representative western blots for hCAT-1 
and hCAT-2A/B in hPMEC from MPH or MSPH placentas (ß-actin: internal control). Lateral panel: hCAT-1 
or hCAT-2A/B/ß-actin densitometry ratios normalized to 1 in the MPH group. *P < 0.05 versus MPH values. 
Values are presented as the mean ± S.E.M. (n = 6).
Parameter MPH MSPH
Vmax (pmol/µg protein/min) 2.39 ± 0.3 1.53 ± 0.18*
Km (µmol/L) 266.2 ± 36.6 408.3 ± 48.6*
Vmax/Km (pmol/µg protein/min/(µmol/L)) 0.009 ± 0.001 0.004 ± 0.0004
MSPH/MPHF 0.44 ± 0.04
Table 3. Kinetic parameters for L-arginine transport. L-arginine transport was assayed (see Methods) in 
hPMEC isolated from placentas from pregnancies with maternal physiological (MPH, TC < 280 mg/dL) or 
supraphysiological hypercholesterolemia (MSPH, TC ≥ 280 mg/dL) (see Methods). Vmax, maximal velocity; and 
Km, apparent Michaelis-Menten constant. MSPH/MPHF is the relative effect of MSPH versus MPH on the maximal 
L-arginine transport capacity (Vmax/Km). *P < 0.05 versus the corresponding values in the MPH group. Values 
are presented as the mean ± S.E.M. (n = 6).
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different areas of the placenta is expected, including microvascular vessels from the sub-chorionic plate, which 
express eNOS and produce NO. Our present study showed that NOS activity, evaluated as L-NAME-inhibited 
L-citrulline content, was measurable in hPMEC. Compared with MPH cells, NOS activity was lower in MSPH 
cells (Fig. 2b). Since in the placenta the main source of NO is eNOS, we suggest that NOS activity determined in 
this study relates with eNOS activity. However, the participation of the inducible NOS isoform (iNOS) needs to 
be determined. Since eNOS protein abundance was not different between MSPH and MPH (Fig. 2c), the lower 
CGRP- and adenosine-induced dilation in MSPH cells may have resulted from reduced NOS activity. These 
results were comparable to those described in HUVEC from MSPH pregnancies3.
Since L-arginine uptake is required for eNOS activity in endothelial cells41,42, reduced L-arginine uptake and 
further restricted delivery to eNOS may occur in cells from MSPH placentas. Our results show that hPMEC from 
MSPH placentas exhibit lower Vmax and Vmax/Km for L-arginine transport as well as higher Km than those from 
MPH placentas (Fig. 3a,b, Table 3). Thus, eNOS should be metabolically less efficient in hPMEC from MSPH 
placentas than in those from MPH placentas due to lower L-arginine availability. Interestingly, this impaired 
L-arginine transport was not associated with changes in the total protein level of the L-arginine transporter 
hCAT-1 or hCAT-2A/B (Fig. 3c). This result is contrary to that described in HUVEC from MSPH pregnancies, 
in which L-arginine uptake was increased. Thus, this result reinforces the concept that the same condition has 
different effects on endothelial cells from the macro- or microvasculature.
Arginases metabolize L-arginine to urea in endothelial cells from the macro-29,43 and microvasculature44,45, 
thus competing with eNOS for substrates. Our results show that arginase activity was lower in hPMEC from 
MSPH placentas without changes in arginase II protein abundance (Fig. 4a,b). Arginase I was undetectable in 
hPMEC. This result differs from the results previously described in HUVEC from MSPH pregnancies, in which 
an increase in arginase activity was shown3. Thus, we suggest that arginases are not involved in the reduction of 
NOS activity described in hPMEC from MSPH placentas.
As shown, the reduced NOS activity and L-arginine uptake was not associated with changes in eNOS, hCAT-1 
or hCAT-2A/B protein abundance. Cholesterol is a key constituent of lipid rafts and caveolae46. Thus, in condi-
tions such as hypercholesterolemia, caveolin is up-regulated, leading to modifications of its localization and mod-
ifications in the signalling of proteins located in caveolae47–49, such as eNOS and hCATs, which are required for 
proper function and NO synthesis50–52. Thus, we speculate that in hPMEC from MSPH placentas, decreased NO 
synthesis may be related to alterations in hCAT and eNOS distribution in the plasma membrane microdomains 
without changes in protein abundance. However, this hypothesis needs to be evaluated in our model.
In human and animal models, a strong association of LDL and HDL levels with endothelial dysfunction and 
atherosclerosis has been established53–55. However, a possible pathogenic role for dyslipidaemia during pregnancy 
has only been suggested3–7,16. Maternal cholesterol carried in LDL and HDL is transferred across the trophoblast 
cells to the basal membrane and then to placental endothelium and neonatal lipoproteins by LDL and HDL 
receptors56–59 and cholesterol transporters such as the ATP binding cassette transporter sub-family A member 
1 (ABCA1) and G member 1 (ABCG1)59. However, how maternal-derived cholesterol is transferred across the 
human placenta is still not fully understood. Expression of some of these receptors and transporters are deregu-
lated in placentas from pregnancies with increased levels of TC and TG (mRNA and protein)9,10, suggesting that 
Figure 4. Arginase activity. (a) Arginase activity was evaluated as urea formation from L-arginine (50 mmol/L, 
60 min, 37 °C) in hPMEC from pregnancies during which the mother exhibited MPH (white) or MSPH (black). 
(b) Representative western blot for arginase II in hPMEC from MPH or MSPH placentas (ß-actin: internal 
control). Lateral panel: Arginase II/ß-actin densitometry ratios normalized to 1 in the MPH group. *P < 0.05 
versus MPH values. Values are presented as the mean ± S.E.M. (n = 6).
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in MSPH, the placenta could modulate the uptake and delivery of maternal lipids. However, it is necessary to 
evaluate the possible pathological consequences of the increase in maternal cholesterol on cholesterol trafficking 
in the placenta (uptake and efflux) to confirm the implication of maternal dyslipidaemia in the placental vascular 
alterations described in this study. In addition, it has been reported that HDL modulates eNOS activity in the 
endothelium49,55,60. However, whether neonatal HDL from MSPH pregnancies also modulates eNOS activity in 
placental endothelium is unknown.
In summary, although MSPH treatment or prevention studies are necessary to establish a causal effect, we 
describe here, for the first time, that MSPH is a pathological maternal condition that impairs placental microvas-
culature dilation as well as NOS activity and L-arginine uptake in hPMEC without changes in arginase activity. 
Finally, the consequences of this maternal condition on the neonatal outcome needs to be determined.
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